By the Top Tier Newswire AI Desk · August 28, 2026 at 5:05 PM ET · reviewed against 4 wire stories
NOVAVAX INC (NVAX) is drawing unusual attention today. Our newswire has captured 4 stories on NVAX across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why NVAX stock is moving today
NVAX stock is moving in a mixed session following news of regulatory approvals for its updated COVID-19 vaccine. The stock opened with a 0.8% gap up from the previous close but has since traded in a narrow range between $8.89 and $9.34. The primary driver is the announcement that the U.S., EU, and Japan have approved the XFG-adapted Nuvaxovid vaccine, which is marketed in partnership with Sanofi and Takeda. The approvals are intended for the 2026, 2027 vaccination season.
What Happened
Novavax announced that its updated vaccine, Nuvaxovid, has received regulatory approvals in three major markets. The vaccine targets the XFG variant of SARS-CoV-2 and is designed for use in the upcoming vaccination season. The company emphasized that the vaccine is protein-based and non-mRNA, with a favorable tolerability profile. The approvals follow a broader trend of updated vaccines being authorized for the current flu season. Novavax’s partners are now positioned to distribute the vaccine in high-risk populations, particularly older adults. The company also highlighted the ongoing public health challenge posed by the virus.
What The Data Shows
The stock has shown mixed performance during the session, opening at $9.12 and reaching a high of $9.34 before declining to $8.89. The last trade stands at $9.22, with 3.7 million shares traded so far, 0.8 times the 3-month average. On the options front, there has been one notable print with a put premium of $5.0 million, indicating bearish positioning. The stock has also seen unusual activity from options traders. Over the past 30 days, sentiment has improved from 60/100 to 65/100. Meanwhile, the 52-week tape has seen 3 fresh 52-week highs and 16 fresh 52-week lows on August 28, 2026.
What To Watch
With no upcoming earnings date provided, investors may want to monitor the breadth of coverage and any follow-up developments regarding vaccine distribution and market adoption.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NVAX · Aug 28 session (5-min) · +2.54% vs prior close · updated 8:44 PM ETAI sentiment, last 36h · averaged over 4 stories · 63/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
15d agoSeeking AlphaBULLISH 67Product/PR
Novavax announces regulatory approvals for updated COVID shot
Novavax (NVAX) says the U.S., EU & Japan approved its updated COVID-19 vaccine targeting the XFG variant, marketed with Sanofi (SNY) and Takeda (TAK). Read more here.
15d agoThe FlyBULLISH 63Product/PR
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
15d agoPR NewswireBULLISH 67Product/PR
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
COVID-19 remains a public health challenge, particularly among older adults and high-risk populations1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers...
17d agoYahoo TopBULLISH 56Product/PR
Novavax Stock Pulls Back After Milestone Vaccine Success
Novavax stock is garnering attention from options traders
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →